Evidence map›Paper›PMID 32341463›Full record

ReviewNature reviews. Rheumatology2020

PAD enzymes in rheumatoid arthritis: pathogenic effectors and autoimmune targets.

Ashley M Curran, Pooja Naik, Jon T Giles, Erika Darrah

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06656169 (Effect of Subcutaneous Polyvidone Collagen Treatment vs Placebo on Clinical Hand Recovery, Biochemical Response and Quality of Life in Adult Rheumatoid Arthritis.), which is not on this map. Cited by 106 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
106citing papers in PubMed, 1 pooled it
14.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06656169 phase1 / phase2completednot on this mapstarted 2021, after this paper: background citation

Effect of Subcutaneous Polyvidone Collagen Treatment vs Placebo on Clinical Hand Recovery, Biochemical Response and Quality of Life in Adult Rheumatoid Arthritis.

TypeinterventionalSponsorInstituto Mexicano del Seguro SocialRan2021 to 2023Enrolled25ConditionsArthritis, RheumatoidArmsSubcutaneous polyvidone collagen, saline solution
3 · Its place in the literature

Who cites it

106 citing papers in PubMed, 1 synthesis or guideline pooled it, 162 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. DNA From Neutrophil Extracellular Traps Restricts Group 3 Innate Lymphoid Cells Function in Intestinal Epithelial Repair via CCDC25.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Periodontitis and Systemic Health: An Interconnected Relationship.Advances in experimental medicine and biology · 2026
    Review
  18. Article
  19. Review
  20. Review

46 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ashley M CurranDivision of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-7735-0437
Pooja NaikDivision of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jon T GilesDivision of Rheumatology, Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA.
Erika DarrahDivision of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. edarrah1@jhmi.edu.ORCID http://orcid.org/0000-0003-1119-0279
Johns Hopkins University · USColumbia University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peptidylarginine deiminases (PADs) have an important role in the pathogenesis of rheumatoid arthritis (RA) owing to their ability to generate citrullinated proteins - the hallmark autoantigens of RA. Of the five PAD enzyme isoforms, PAD2 and PAD4 are the most strongly implicated in RA at both genetic and cellular levels, and PAD inhibitors have shown therapeutic efficacy in mouse models of inflammatory arthritis. PAD2 and PAD4 are additionally targeted by autoantibodies in distinct clinical subsets of patients with RA, suggesting anti-PAD antibodies as possible biomarkers for RA diagnosis and prognosis. This Review weighs the evidence that supports a pathogenic role for PAD enzymes in RA as both promoters and targets of the autoimmune response, as well as discussing the mechanistic and therapeutic implications of these findings in the wider context of RA pathogenesis. Understanding the origin and consequences of dysregulated PAD enzyme activity and immune responses against PAD enzymes will be important to fully comprehend the pathogenic mechanisms involved in this disease and for the development of novel strategies to treat and prevent RA.

Indexed as

Anti-Citrullinated Protein AntibodiesArthritis, RheumatoidAutoantibodiesAutoantigensCitrullinationCross ReactionsGenetic Predisposition to DiseaseHumansLung Diseases, InterstitialProtein-Arginine DeiminasesProtein-Arginine Deiminase Type 2Protein-Arginine Deiminase Type 3Protein-Arginine Deiminase Type 4Severity of Illness IndexAnti-Citrullinated Protein AntibodiesAutoantibodiesAutoantigensProtein-Arginine DeiminasesProtein-Arginine Deiminase Type 2Protein-Arginine Deiminase Type 3Protein-Arginine Deiminase Type 4

Identifiers

PMID32341463
OpenAlexW3019144294

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.